Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 4 January 2019, 11:18 HKT/SGT
Share:
    

Source: Eisai
Eisai's Etak Antimicrobial Spray Alpha Wins Nikkei Business Daily Awards for Superiority at the 2018 Nikkei Superior Products and Services Awards
For Dealing with Viruses and Bacteria! Antimicrobial Barrier that Lasts for 1 Week

TOKYO, Jan 4, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that it received a "Nikkei Business Daily Awards for Superiority" for its Etak Antimicrobial Spray Alpha, which contains long-acting antimicrobial agent Etak, at the 2018 Nikkei Superior Products and Services Awards sponsored by Nikkei Inc.

Since 1982, the Nikkei Superior Products and Services Awards are awarded every year to superior new products and services, and this marks the 37th iteration of the awards. Without accepting applications for nomination, award recipients are selected from among the approximately 20,000 new products and services reported in The Nikkei, The Nikkei Business Daily, The Nikkei Marketing Journal, The Nikkei Veritas, Nikkei.com (the Nikkei's electronic edition) and the Nikkei Asian Review. For screening, products and services are comprehensively assessed across six aspects:

1) Excellence in technology development
2) Cost-effectiveness
3) Contribution to business performance
4) Growth potential
5) Uniqueness
6) Commercial impact and social impact.

Etak Antimicrobial Spray Alpha was selected for offering the concept of "long-acting antimicrobial action" in the anti-virus/bacteria product market and for developing a new customer segment in consideration of ease-of-use for child-raising families due to being non-alcohol, as well as for cost-performance by providing an antimicrobial effect that lasts for one week and with 250 ml can be used for approximately 800 pushes.

Etak Antimicrobial Spray Alpha was born from a previously unheard of concept of keeping viruses and bacteria at bay with an antimicrobial barrier. The product is a spray that contains Etak, a patented long-acting antimicrobial agent developed by Professor Hiroki Nikawa of the Department of Oral Biology and Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. Not only is it possible to eliminate viruses and bacteria by simply spraying the product, the antimicrobial component is bound to the spray area, providing an antimicrobial effect that lasts for one week even after drying.

Spraying Etak Antimicrobial Spray Alpha beforehand creates an antimicrobial barrier on various objects in the surrounding environment which keeps away viruses and bacteria. Spraying coats, gloves and bags before going out will repel viruses and bacteria, and also helps prevent the spread of viruses and bacteria indoors via hands and objects. A single bottle of Etak Antimicrobial Spray Alpha can be used in a variety of lifestyle scenes including on door knobs, tables, bedding, kitchen items such as counters, chopping boards and knives, as well as in bathrooms and toilets. In addition, the product is scentless and contains no alcohol, making it also ideal for children's items such as toys, as well as nursing care items.

Together with providing Etak Antimicrobial Spray Alpha to contribute to consumers who wish to keep viruses and bacteria at bay, Eisai remains committed to ensuring the delivery of products that satisfy the diversified needs of consumers and to further increasing the benefits provided to them.


Contact:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 1, 2024 12:56 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Oct 31, 2024 12:56 HKT/SGT
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 10:33 HKT/SGT
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 17, 2024 19:01 HKT/SGT
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Oct 17, 2024 14:59 HKT/SGT
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: